drugset
drugset / Trial / NCT01914718

Dose-adjusted EPOCH-R in MYC Positive DLBCL

NCT01914718 ↗

Phase 2 Terminated 26 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the efficacy and toxicity of dose-adjusted EPOCH-R in patients with MYC positive diffuse large B-cell lymphoma.

Timeline

Start
2013-02
Primary completion
2015-12
Completion
2017-12

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual of eligible patients”

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 10 mg/m2 Intravenous
Background Etoposide Small molecule 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 50 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 0.4 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma